Efficiency of combined methotrexate/chloroquine therapy in adjuvant-induced arthritis

• Published in: Fundamental & clinical pharmacology 2005-08, Vol.19 (4), p.479-489
• Main Authors: Silva, M.A.R.C.P., Ishii-Iwamoto, E.L., Bracht, A., Caparroz-Assef, S.M., Kimura, E., Cuman, R.K.N., Bersani-Amado, C.A.
• Format: Article
• Language: English
• Subjects: Acid Phosphatase - metabolism; Alanine Transaminase - metabolism; Alkaline Phosphatase - metabolism; Animals; anti-inflammatory protection; Arthritis, Experimental - drug therapy; Arthritis, Experimental - enzymology; Aspartate Aminotransferases - metabolism; Biological and medical sciences; Body Weight - drug effects; chloroquine; Chloroquine - administration & dosage; Drug Therapy, Combination; hepatotoxicity; induced arthritis; Liver - enzymology; Male; Medical sciences; methotrexate; Methotrexate - administration & dosage; Pharmacology. Drug treatments; phosphatase; Rats; transaminase
• ISSN: 0767-3981; 1472-8206
• DOI: 10.1111/j.1472-8206.2005.00346.x

The present study evaluates the effects of methotrexate (MTX) and chloroquine (CQ), and of combined MTX + CQ treatment, on the inflammatory response and on plasma and liver phosphatase and transaminase activities, employing an adjuvant‐induced arthritis model in rats. Arthritis was induced by the intradermal injection of a suspension of Mycobacterium tuberculosis in mineral oil into the plantar surface of the hind paws. Development of the inflammatory response was assessed over a 21‐day period. Animal groups received either: (i) MTX, administered i.p., weekly, in 0.15, 1.5, 3, 6 or 12 mg/kg doses; (ii) CQ, given intragastrically, in daily 25 or 50 mg/kg doses; or (iii) MTX + CQ, administered in two combinations (MTX1.5 mg/kg + CQ50 mg/kg, or MTX6 mg/kg + CQ50 mg/kg). At the end of the experimental period, the animals were anesthetized and killed, blood and liver samples were collected and prepared for measurement of acid and alkaline phosphatase (AP, ALP), and aspartate (AST) and alanine aminotransferase (ALT) activities. MTX at 6 and 12 mg/kg reduced the inflammatory response while CQ had no effect. MTX6 mg/kg + CQ50 mg/kg reduced the inflammatory response similar to MTX12 mg/kg, without affecting the bone marrow. Plasma AP and liver ALP activities were very elevated in the arthritic rats. While MTX treatment partially reduced both plasma AP and liver ALP activities at all doses used in the arthritic rats, CQ treatment reduced plasma AP, but increased liver AP activity. MTX + CQ treatment decreased plasma AP and liver ALP activities in the arthritic rats to control values. Plasma and liver AST activities were unaltered in the arthritic rats, and were unaffected by treatment. However, plasma and liver ALT activities were significantly reduced in the arthritic rats. While MTX or CQ treatment did not alter plasma transaminase activity in the arthritic rats, after MTX + CQ treatment, plasma ALT activity returned to normal values. In conclusion, the present data suggest that MTX + CQ treatment provides more effective anti‐inflammatory protection against adjuvant‐induced arthritis than does MTX alone, reverting the alterations in enzyme activities induced by this inflammatory disease in rats.